GRDX underwent a major corporate transformation including a name change to Entero Therapeutics, substantial dilution with shares increasing 135%, and a concerning shift to negative stockholders' equity of -$3.9M despite massive asset growth.
The company has fundamentally changed its identity and capital structure through acquisitions and financing activities, creating significant dilution risk for existing shareholders. The negative stockholders' equity position indicates the company is technically insolvent on a book value basis, while the 96% cash depletion to just $163K creates immediate liquidity concerns despite the large asset base increase.
GRDX's financials reflect a dramatic corporate restructuring with total assets surging 1,140% to $85.4M and current assets jumping 1,584% to $83.5M, likely from acquisitions and financing activities. However, the company burned through 96% of its cash reserves to just $163K while liabilities increased 742% to $27.6M, pushing stockholders' equity deeply negative to -$3.9M. Despite improved operating cash flow performance (-$9.2M vs -$12.4M), the severe cash depletion and technical insolvency position create immediate financial distress concerns that overshadow the asset growth.
Current assets grew 1584.3% — improving short-term liquidity or inventory/receivables build.
Capital expenditure jumped 1567.6% — major investment cycle underway; assess returns on deployment.
Asset base grew 1140.8% — expansion through organic growth, acquisitions, or capital deployment.
Current liabilities surged 779.1% — significant near-term obligations; verify ability to meet short-term debt.
Liabilities grew 741.6% — significant increase in debt or obligations, assess impact on financial flexibility.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Cash declined 95.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
R&D spending cut 82% — could signal cost discipline or concerning reduction in innovation investment.
Interest expense surged 41.5% — significant debt increase or rising rates materially impacting earnings.
Operating cash flow grew 25.5% — strong conversion of earnings to cash, healthy business fundamentals.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →